Nothing Special   »   [go: up one dir, main page]

AR095502A1 - Anticuerpos profármaco contra el inhibidor de la vía del factor tisular - Google Patents

Anticuerpos profármaco contra el inhibidor de la vía del factor tisular

Info

Publication number
AR095502A1
AR095502A1 ARP140101107A ARP140101107A AR095502A1 AR 095502 A1 AR095502 A1 AR 095502A1 AR P140101107 A ARP140101107 A AR P140101107A AR P140101107 A ARP140101107 A AR P140101107A AR 095502 A1 AR095502 A1 AR 095502A1
Authority
AR
Argentina
Prior art keywords
inhibitor
propharm
antibodies
antibodies against
prodrug
Prior art date
Application number
ARP140101107A
Other languages
English (en)
Inventor
Wang Zhuozhi
Murphy John
Hermiston Terry
Zhu Ying
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of AR095502A1 publication Critical patent/AR095502A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación proporciona anticuerpos profármaco que se unen específicamente al inhibidor de la vía del factor tisular (TFPI) únicamente tras la exposición a proteasas de la cascada de coagulación. Los anticuerpos profármaco descritos son útiles para tratar trastornos hemorrágicos, tales como hemofilia. Cuando se usa en dichos tratamientos, estos anticuerpos profármaco muestran una mayor semivida respecto a otros anticuerpos anti-TFPI a la vez que mitigan el potencial de efectos secundarios tales como trombosis.
ARP140101107A 2013-03-15 2014-03-14 Anticuerpos profármaco contra el inhibidor de la vía del factor tisular AR095502A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361794024P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095502A1 true AR095502A1 (es) 2015-10-21

Family

ID=51537758

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101107A AR095502A1 (es) 2013-03-15 2014-03-14 Anticuerpos profármaco contra el inhibidor de la vía del factor tisular

Country Status (10)

Country Link
US (1) US20160009817A1 (es)
EP (1) EP2970498A4 (es)
JP (1) JP2016514687A (es)
CN (1) CN105209496A (es)
AR (1) AR095502A1 (es)
CA (1) CA2906095A1 (es)
HK (1) HK1215262A1 (es)
TW (1) TW201522368A (es)
UY (1) UY35459A (es)
WO (1) WO2014144689A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
KR102182485B1 (ko) 2013-05-28 2020-11-25 카오슝 메디칼 유니버시티 단백질 약물의 불활성화를 위한 항체 로커
KR102068915B1 (ko) 2015-08-19 2020-01-22 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
CA3003482A1 (en) 2015-11-19 2017-05-26 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERIAL ALBUMIN BINDING PROTEIN
US11230610B2 (en) * 2016-12-09 2022-01-25 Seagen Inc. Bivalent antibodies masked by coiled coils
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
WO2018204717A1 (en) * 2017-05-03 2018-11-08 Harpoon Therapeutics, Inc. Compositions and methods for adoptive cell therapies
CN113896792A (zh) 2017-05-12 2022-01-07 哈普恩治疗公司 间皮素结合蛋白质
WO2019036433A2 (en) 2017-08-16 2019-02-21 Bristol-Myers Squibb Company ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION
KR20220111743A (ko) 2017-10-13 2022-08-09 하푼 테라퓨틱스, 인크. B 세포 성숙화 항원 결합 단백질
US20210269530A1 (en) * 2018-05-14 2021-09-02 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
US20220251206A1 (en) 2019-06-11 2022-08-11 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
CN113354715B (zh) * 2021-05-07 2023-03-17 暨南大学 Egfr的改造的结合蛋白及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
CN101031588A (zh) * 2004-06-01 2007-09-05 多曼蒂斯有限公司 药物组合物，融合物和结合物
EP1765846A4 (en) * 2004-07-13 2010-02-17 Cell Genesys Inc AAV VECTOR COMPOSITIONS AND ITS USE IN PROCESSES FOR INCREASING IMMUNOGLOBULIN EXPRESSION
US20060252096A1 (en) * 2005-04-26 2006-11-09 Glycofi, Inc. Single chain antibody with cleavable linker
EP2532676B1 (en) * 2007-08-15 2017-03-22 Bayer Pharma Aktiengesellschaft Protease-regulated antibody
US20090304719A1 (en) * 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
WO2010072691A1 (en) * 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
JP5851842B2 (ja) * 2009-01-12 2016-02-03 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. 改変した抗体組成物、それを作製および使用する方法
US10584181B2 (en) * 2009-12-04 2020-03-10 Genentech, Inc. Methods of making and using multispecific antibody panels and antibody analog panels
WO2011101435A1 (en) * 2010-02-19 2011-08-25 Novo Nordisk A/S Activatable constructs
ES2642512T3 (es) * 2010-03-01 2017-11-16 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
JP5730983B2 (ja) * 2010-03-19 2015-06-10 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉ阻害剤および使用方法
JP2013533871A (ja) * 2010-06-30 2013-08-29 ノヴォ ノルディスク アー／エス 組織因子経路インヒビターに特異的に結合することが可能な抗体

Also Published As

Publication number Publication date
EP2970498A4 (en) 2016-11-23
CN105209496A (zh) 2015-12-30
JP2016514687A (ja) 2016-05-23
TW201522368A (zh) 2015-06-16
EP2970498A1 (en) 2016-01-20
US20160009817A1 (en) 2016-01-14
UY35459A (es) 2014-10-31
WO2014144689A1 (en) 2014-09-18
CA2906095A1 (en) 2014-09-18
HK1215262A1 (zh) 2016-08-19

Similar Documents

Publication Publication Date Title
AR095502A1 (es) Anticuerpos profármaco contra el inhibidor de la vía del factor tisular
CY1124061T1 (el) Τρικυκλικη ενωση ως αντικαρκινικοι παραγοντες
NI201500094A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
CO2018001473A2 (es) Anticuerpos inhibidores de vía del factor tisular y usos de los mismos
CL2017000820A1 (es) Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
CY1121710T1 (el) Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
DOP2015000234A (es) COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO.
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
PE20160190A1 (es) Anticuerpos anti-fgfr2iiib afucosilados
UY35787A (es) Composiciones útiles para tratar trastornos relacionados con kit
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
EA201690549A1 (ru) Арилэфиры и их применения
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
UY36747A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen
CR20170219A (es) Inhibidores del bromodominio
ECSP14030779A (es) Inhibidores del nampt
EA201591705A1 (ru) Композиции и способы для диагностики и лечения рака печени
UY35493A (es) Métodos para el tratamiento de la osteogénesis imperfecta
PE20160031A1 (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y metodos de uso
NI201500055A (es) Tratamiento de cáncer de próstata con inhibidores de quinasa tor
GT201300267A (es) Isoxazolinas como agentes terapéuticos

Legal Events

Date Code Title Description
FB Suspension of granting procedure